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A B S T R A C T
In clinical setting, congestive heart failure (CHF) and chronic kidney disease (CKD) often co-exist in
patients due to common underlying predisposing factors. An intricate equilibrium between the
cardiovascular and renal system is maintained through rennin angiotensin–aldosterone axis and
autonomic nervous system. Consequent to favorable hemodynamic modiﬁcation, angiotensin
converting enzyme inhibitors (ACEI) and angiotensin receptor blocking (ARB) therapy have proven
to be an indispensable aspect of heart failure management with morbidity and mortality beneﬁt.
Additionally, progression to end stage renal failure may be halted by renin angiotensin aldosterone
system (RAAS) blockade in patients with preexisting renal dysfunction. However, concern over the safety
of RAAS blockade in presence of renal impairment has led to profound underutilization of these drugs in
CHF patients with renal insufﬁciency. This review aims to provide a simpliﬁed guide to pathophysiology
and management options of this perplexing situation.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Queries abound on the management strategy to follow when
chronic kidney disease and heart failure co-exist in a patient.
Among treatment options available, most perplexing question is
whether to initiate or continue renin angiotensin aldosterone
blocking agents in such patients. Despite of beneﬁcial cardio-renal
interactions of these medications, an apprehension over possible
renal worsening often leads to its underuse in clinical practice.
Through this review, we hope to outline guideline based simpliﬁed
management strategy in such cases.
Renal insufﬁciency management is a signiﬁcant aspect of heart
failure (HF) treatment not only because of its high prevalence
consequent to shared risk factors, but also its association with
mortality.1 Major randomized trials have shown that ACEI and/or
ARB in addition to standard cardiac medications have survival
beneﬁt in HF patients.2 However, under representation of
coexistent renal insufﬁciency in HF trials has led to skewed data
and failure to generalize these results among patients having
concomitant kidney disease.3 Moreover chronic kidney disease* Corresponding author at: Department of Cardiology, Government Medical
College, Kozhikode, Kerala 673008, India.
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licenses/by-nc-nd/4.0/).(CKD) patients are frequently refractory to conventional treatment
and are at increased risk of adverse effects with HF medications.4
Serum creatinine (sCr) level despite being an insensitive
measure of glomerular ﬁltration rate (GFR), it is often the favored
parameter to assess the renal impairment in clinical practice. It has
a nonlinear association with GFR, which varies with age, sex and
body mass. To overcome these limitations, estimated glomerular
ﬁltration rate (eGFR) estimated by Cockcroft–Gault equation is
now considered ideal for assessing renal function. Renal insufﬁ-
ciency is diagnosed with eGFR <90 ml/min/1.7 m2 and various
stages categorized depending on eGFR values. Chronic kidney
disease is deﬁned as eGFR <60 ml/min/1.73 m2 for 3 months,
with or without kidney damage.5
2. Pathophysiology
HF is a multifaceted syndrome that is consequent to any
structural or functional impediment in ventricular ﬁlling or
ejection of blood.6 It is diagnosed clinically based on manifesta-
tions secondary to congestion of systemic and/or pulmonary
venous systems. HF classiﬁcation based on left ventricular ejection
fraction has prognostic and therapeutic importance. Even in
presence of normal ejection fraction, excess volume overload
consequent to renal dysfunction may result in clinical features of
heart failure.7 Moreover assessment of cardiac failure is difﬁcult in
volume overloaded patients with renal dysfunction. Ventricularnverting enzyme inhibitors and receptor blockers in heart failure
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Fig. 1. Pathophysiologic pathways of RAAS interaction between heart failure and renal dysfunction. CHF – congestive heart failure, CKD – chronic kidney disease, RAAS – renin
angiotensin aldosterone system, ACEI – angiotensin converting enzyme inhibitors, ARB – angiotensin receptor blocker, PAI-1 – plasminogen activator inhibitor-1, CVP –
central venous pressure.
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in patients with CKD may contribute to the appearance or
worsening of HF in patients with left ventricular dysfunction.8
Clinical manifestation of congestive heart failure (CHF) is present
in approximately 20% of ESRD patients.9 Additionally, hemody-
namic alteration produced by cardiac dysfunction may lead to
worsening of renal function as adequate mean arterial pressure is
necessary to maintain renal perfusion and glomerular ﬁltration.
Balance between the cardiovascular and renal system is main-
tained by an intricate link mediated through renin angiotensin–
aldosterone axis and autonomic nervous system10 (Fig. 1).
3. Angiotensin converting enzyme inhibitors (ACEI) and
angiotensin receptor blockers (ARB)
ACEI and ARB are one of the most preferred therapeutic agents
for management of hypertension. Their favorable hemodynamic
alteration includes reduction of cardiac preload, afterload and
systolic ventricular wall stress resulting in augmented cardiac
output without proportionate increase in oxygen consumption.11
This hemodynamic alteration maintains glomerular ﬁltration by
improving the renal perfusion and promoting sodium excretion.
Hence they are instrumental in long term management of patients
with hypertension, CHF, diabetic and non-diabetic nephropathy
providing mortality beneﬁt.12 By preventing degradation of
bradykinin, ACEI may improve organ perfusion enhancing kinin
induced peripheral vasodilatation. But occasionally these drugs
may result in mild renal insufﬁciency consequent to reduction in
GFR. This functional renal insufﬁciency often occurs when renal
perfusion is reduced secondary to decline in mean arterial pressure
or when the GFR is highly angiotensin II dependent as in conditions
like volume depletion, bilateral renal artery stenosis or renal artery
stenosis in a single functional kidney as in transplant recipient.13
Although there is no creatinine value at which initiation of ACEI is
contraindicated, it is advisable to be cautious while initiation of
these medications when serum potassium is >5.5 mEq/L or
systolic blood pressure is <90 mmHg. Usually ACEI and ARB
associated renal insufﬁciency is transient and reversible with
discontinuation of drugs.14Please cite this article in press as: Muneer K, Nair A. Angiotensin-co
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Renal blood ﬂow and GFR are maintained over a wide range of
mean arterial pressure by angiotensin II and sympathetic nervous
system mediated renal auto-regulation.10 When renal perfusion
pressure falls as in case of CHF, there is increased production of
renin from juxtaglomerular cells and subsequent angiotensin II
production. This leads to vasoconstriction of post-glomerular
efferent arterioles and consequently glomerular capillary pressure
increases. Angiotensin also increases distal convoluted tubule
sodium reabsorption through aldosterone secretion. Thirst center
activation along with free water absorption by ADH secretion helps
to maintain intravascular volume. As a result, GFR is maintained
despite reduction in mean arterial pressure.
RAAS blockade leads to reduction in systemic vascular
resistance, sodium reabsorption, aldosterone and ADH secretion.11
These beneﬁcial effects of ACEI and ARB in patients with CHF is also
associated with fall in GFR due to preferential dilatation of post-
glomerular efferent arterioles resulting in reduction in ﬁltration
pressure. In a normotensive patient, this leads to mild (usually
<20%) increase in serum creatinine. But in patients with MAP is
less than 60 mm of Hg, diuretic induced hypovolemia or those with
signiﬁcant renal arterial disease, use of ACEI and ARB can lead to
marked reduction in glomerular ﬁltration pressure and acute
worsening in renal function leading to acute renal failure (ARF).13
In CONCENSUS II trial (Cooperative North Scandinavian Enalapril
Survival Study II) there is 2.4% incidence of acute renal dysfunc-
tion15 and in SOLVD trial (Studies of Left Ventricular Dysfunction)
there is 4% relative likelihood of developing ARF with use of ACEI
and ARB.16 ACE inhibitors and ARBs can be used as alternatives of
each other, if the preferred class cannot be used and should be
gradually titrated to maximum tolerated dose. Concept of
increased inhibition of the renin system to improve heart failure
outcomes was marred with hurdles. There are conﬂicting reports
about use of combination of ACEI and ARB in heart failure patients.
While trials like ONTARGET and ValHeFT showed no clinical
beneﬁt of such combination, others trials like CHARM- Added
showed decreased hospitalization.17–19 However, the important
point to note in these trials are remarkably low proportion ofnverting enzyme inhibitors and receptor blockers in heart failure
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Table 1
Causes of renal dysfunction on RAAS blockade therapy.
1. Poor renal perfusion Heart failure exacerbation, low cardiac output, dehydration, volume depletion
2. Renovascular disease Bilateral renal artery stenosis, stenosis of single or dominant kidney, diffuse atherosclerosis of pre-glomerular vessels
3. Drugs NSAIDS, cyclosporine, radiocontrast
4. Infections Bacterial, viral, fungal
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the generalizability of the ﬁndings to patients with chronic kidney
disease is not justiﬁed.
5. Causes of ARF on ACEI and ARB therapy
ARF can be deﬁned as increase in serum creatinine >0.5 mg/dl,
if serum creatinine was <2 mg/dl or an increase of >1 mg/dl if
initial serum creatinine was >2 mg/dl.13 ARF in the setting of
chronic ACEI and/or ARB administration signify a change in
systemic hemodynamics secondary to worsening heart failure
causing extra cellular ﬂuid accumulation and reduction in mean
arterial pressure or aggressive diuresis causing intravascular
volume depletion (Table 1). The probability of deterioration of
renal function increases in CHF patients with CKD as the
compensatory hyper ﬁltration in remaining glomeruli is removed
by ACEI and ARB. Renal ﬁltration pressure is signiﬁcantly reduced
with ACEI and ARB especially in patients on with long acting
formulations and in those requiring renal clearance when MAP
falls below 60 mm of mercury. Higher incidence of elevated serum
creatinine documented in patients already on diuretic therapy
often return to pretreatment level when diuretics doses where
reduced.20
In patients with bilateral renal artery stenosis, diffuse
atherosclerosis and functional single kidney, ACEI and ARB can
signiﬁcantly worsen renal function as they are dependent on RAAS
to maintain glomerular ﬁltration. Pre-glomerular afferent arterio-
lar constriction due to NSAID and hypertension can lead to ARF in
patients on ACEI and ARB. A rise of creatinine up to 20% can be
anticipated and this by itself is not an indication of discontinuing
these medications. ACEI and ARB can also potentiate radiocontrast
induced renal injury and this may be aggravated by concomitant
use of NSAID.10
6. Management of ARF
Management of ARF centers on treatment of life threatening
situations, attempts to halt or reverse renal deterioration,
modiﬁcations of identiﬁable precipitating cause and if unsuccess-
ful providing support by renal replacement anticipating functional
recovery. The deterioration in renal function induced by inhibition
of the RAAS does not have the same adverse prognostic
implications as other causes of ARF in HF.21 Moreover diuretic
induced hypokalemia is often offset by chronic ACEI and ARB
therapy.
Anxiety ascribed to possible deterioration of renal functions
and resultant complication is the key rationale implicated in
underutilization of these drugs in CHF patients with renal
insufﬁciency. ACEI and ARB are generally well tolerated by
patients with mild to moderate renal insufﬁciency. Judicious
monitoring of serum creatinine level in patients on RAAS blockade
therapy may help in identiﬁcation and prevention of progressive
renal function deterioration. Degree of renal deterioration that
mandates dose reduction or discontinuation of RAAS blockade is
presently uncertain. Although the discontinuation of RAAS
blockade often normalizes renal parameters, it is not the preferred
initial therapeutic choice as mild elevation in serum creatinine is
manifestation of hemodynamic effect of RAAS blockade.22 HigherPlease cite this article in press as: Muneer K, Nair A. Angiotensin-co
and chronic kidney disease – Demystifying controversies, Indian Hecreatinine level is evident in patient with more intensive blood
pressure control as evidenced by recently published SRPINT trial.23
Raise in serum creatinine is usually transient as shown in
CONSENSUS trial in which only 9% patients had persistent
elevation creatinine as compared to 30% of study population in
ﬁrst follow-up. In SOLVD trial deterioration of renal function was
comparable in patients on ACEI and placebo (16% vs 12%,
respectively). These studies have proved beyond doubt that with
proper monitoring of renal parameters, ACEI can be safely used in
CKD patients. Though it is safe in majority, patients planned for
institution of ACEI and ARB therapy should have baseline
estimation of eGFR. Routine monitoring of serum creatinine and
electrolytes must be done in all CHF patients in whom RAAS
blockade is initiated. When RAAS blockade is initiated at GFR and
potassium levels of <60 ml/min/1.73 m2 and 4.5 mEq/L, respec-
tively, regular monitoring for renal parameters must be done
preferably at 4 weeks interval. If the percentage of GFR decline
after initiation is <15%, more liberal approach of monitoring
creatinine and potassium levels at 4–12 weeks interval may be
planned.
Studies suggest an increase in creatinine of up to 50% above
baseline to an absolute value <3 mg/dl or reduction in eGFR of
value less than 25 ml/min/1.73 m2 whichever is the smaller, is
acceptable. In such cases serum creatinine should be checked after
2 weeks after stopping of offending nephrotoxic medications like
NSAIDS, correction of hypovolemia and/or reduction in diuretic
dosage. Azotemia in ACEI and ARB induced renal failure is usually
completely reversible unless tubular necrosis sets in. Hence
intensive follow-up in HF patients with CKD presenting with
oliguria, azotemia and hypotension is vital. In cases with
progressive renal failure despite above measures, the dose of
the RAAS-inhibitor should be halved and serum creatinine strictly
monitored. Guidelines advocate discontinuation of RAAS blockade
with an increase in creatinine of up to 100% above baseline or to an
absolute value >3.5 mg/dl (310 mmol/l) or an eGFR <20 ml/min/
1.73 m2.21 In cases with severe renal dysfunction, fear of life
threatening hyperkalemia hampers use of ACEI and ARB. It is
advisable to initiate ACEI or ARB in incremental doses as tolerated
in euvolemic patients. Majority of ACEI and ARB are eliminated
during hemodialysis. Hence it is safe to continue these medications
in CKD patients on renal replacement therapy, often needing post-
dialysis substitution. Hypertensive patients having CHF with
advanced renal dysfunction may be treated with non-dialyzable
ACEI with hepatic clearance (e.g., Fosinopril).24
7. Conclusion
RAAS blockade is not only a vital aspect of HF management but
also prevents progression of renal dysfunction providing morbidity
and mortality beneﬁt. CKD must not be considered as contraindi-
cation for institution of ACEI or ARB medications but caution must
be exercised in elderly and patients with severe renal dysfunction
as they are inadequately represented in trials. Their safety in this
selected population needs to be substantiated by further studies.
With Cardiovascular disease being the main cause of mortality in
CKD patients, with proper monitoring of renal parameters, ACEI
and ARB can be safely used in CHF patients having mild to
moderate renal dysfunction.nverting enzyme inhibitors and receptor blockers in heart failure
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